{
    "clinical_study": {
        "@rank": "18402", 
        "arm_group": [
            {
                "arm_group_label": "Januvia (Sitagliptin)", 
                "arm_group_type": "Experimental", 
                "description": "Sitagliptin 100 mg a day for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare the rate of healing as well as percent of\n      wounds healed in Type II diabetic patients with chronic foot ulcerations receiving\n      sitagliptin versus placebo.\n\n      The hypothesis for this study is that subjects receiving daily doses of sitagliptin in\n      combination with their regular antihyperglycemic medications will result in increased\n      healing rates as well as a greater number of healed wounds as compared to subjects receiving\n      placebo and their regular antihyperglycemic medications."
        }, 
        "brief_title": "Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers", 
        "condition": "Insulin Dependent Diabetes Mellitus (Type II Diabetes)", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female age >18\n\n          -  Type II Diabetes with glycated hemoglobin (hemoglobin A1C) of < 11\n\n          -  Currently on an oral hyperglycemic medication other than sitagliptin\n\n          -  A chronic wound defined as the lack of wound healing progress of <15% per     week or\n             50% over a month period\n\n          -  Ankle brachial index of > 0.80\n\n          -  Wound located on the foot or ankle (Wagner Grade 1,2)\n\n          -  Able to comply with the requirements of the research trial\n\n        Exclusion Criteria:\n\n          -  Current use of dipeptidyl-peptidase four (DPP-4) inhibitor or glucagon like peptide\n             one (GLP-1)agonist\n\n          -  End stage renal disease\n\n          -  Currently enrolled in another research trial that involves treatment of the wound\n\n          -  Active infection of the wound\n\n          -  Wound that probes to bone with osteomyelitis (Wagner Grade 3)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015910", 
            "org_study_id": "MISP-RC50959"
        }, 
        "intervention": [
            {
                "arm_group_label": "Januvia (Sitagliptin)", 
                "description": "Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Sugar pill manufactured to mimick Sitagliptin 100mg pill.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Paul Kim, DPM", 
                "phone": "202-444-3059"
            }, 
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20007"
                }, 
                "name": "Medstar Georgetown University Hospital"
            }, 
            "investigator": {
                "last_name": "Paul Kim, DPM", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers", 
        "overall_contact": {
            "last_name": "Paul J Kim, DPM", 
            "phone": "202-444-3059"
        }, 
        "overall_official": {
            "affiliation": "Georgetown University", 
            "last_name": "Paul J Kim, DPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.", 
            "measure": "Percent Wounds Healed", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015910"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Georgetown University", 
            "investigator_full_name": "Paul J. Kim, DPM", 
            "investigator_title": "Doctor of Podiatric Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Georgetown University", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Georgetown University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}